Trial: 201911080

A Phase II Study to Evaluate the Safety and Efficacy of OQL011 on VEGFR Inhibitor-Associated Hand-foot Skin Reaction in Cancer Patients Study Number OQL011B002

Phase

II

Principal Investigator

Anadkat, Milan

Disease Site

Colon; Esophagus; Kidney; Liver; Rectum; Small Intestine; Stomach; Thyroid

Learn more about this study at: clinicaltrials.gov